Kornimate/medical-research-clean huggingface dataset:
a study of cognitive-behavioral therapy for rumination disorder

Conditions: Rumination Disorder

Summary: the primary aim of this study is to pilot cognitive behavioral therapy (cbt-rd) for 10 individuals ages 10 and older who have rumination disorder

rumination disorder (rd; also known as "rumination syndrome") is a disordered eating behavior characterized by the repeated regurgitation of food during or soon after eating. the frequency of repeated regurgitation of food typically occurs at least a few times per week, frequently daily with subsequent re-chewing, re-swallowing, or spitting out of the regurgitated material. the widely used technique for treatment of rd has typically been diaphragmatic breathing, which works by serving as a competing response to abdominal wall contractions, which is hypothesized to trigger regurgitation. however, the efficacy of diaphragmatic breathing remains unknown and has mainly been delivered through a one-session instruction with an occasional follow-up. in the absence of evidence-based treatments for rd, the investigators, alongside a collaboration with dr. jennifer thomas at the eating disorders clinical and research program (edcrp) at massachusetts general hospital, have created a manualized treatment, cognitive-behavioral therapy for rumination disorder (cbt-rd) informed by published case reports and currently in use at edcrp at massachusetts general hospital and the psychological services center at drexel university. cbt-rd targets the habitual contraction of the abdominal wall and preceding events through the use of habit reversal, using primarily diaphragmatic breathing as a competing response. this study involves a phone screen to determine eligibility, followed by 5-8 sessions of cbt-rd (approximately 50 minutes each). a battery of questionnaires will be administered at pre-treatment, post-treatment, and 3-month follow-up intervals.

Eligibility criteria:
inclusion criteria: * age 10 or above * experience repeated regurgitation of food during or soon after eating, consistent with rumination disorder * if applicable, have stable psychiatric medication for the past three months exclusion criteria: * currently engage (in past three months) in any regular compensatory behaviors (e.g., self-induced vomiting, laxative/diuretic use) * current diagnosis of anorexia nervosa * acute suicide risk * are currently receiving psychological treatment for rumination disorder * co-morbid clinically significant psychological disorder that would require attention beyond the study treatment (e.g., psychotic disorder, substance dependence) * current pregnancy
signature of the host response to a respiratory viral infection, in the prediction of bronchiolitis obliterans

Conditions: Allogeneic Hematopoietic Stem Cell Recipients; Acute Respiratory Infection; Parainfluenza Virus (PIV)

Summary: bronchiolitis obliterans (bo) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(gvhd) after allogeneic hematopoietic stem cell transplantation (hsct). the pathophysiology of bo is, however, poorly known. the available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (piv), respiratory syncytial virus, metapneumovirus). it is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. the objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a bo is associated with a specific signature we will evaluate the predictive signature of a bo after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a bo at 2 months after the infection.


Eligibility criteria:
inclusion criteria : * adults having received a hematopoietic stem cell transplantation for less than two years * availability of respiratory function tests prior to infection * presence of piv respiratory infection documented by identification of the virus by pcr in the upper and/or lower respiratory tract * symptoms of respiratory infection ≤ 5 days * signed informed consent exclusion criteria: * presence of a respiratory virus infection other than piv * viral respiratory co-infections * bacterial or fungal respiratory infections * treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses * patient not affiliated or beneficiary of a social security system * patient deprived of liberty or protected * pregnant or breastfeeding woman
optimal dosage of acetazolamide for osa treatment

Conditions: Obstructive Sleep Apnea

Summary: acetazolamide, a carbonic anhydrase inhibitor, has received some attention as potential treatment for obstructive sleep apnea (osa). it produces a metabolic acidosis by excreting bicarbonate, thereby stimulating baseline ventilation. evidence suggests that acetazolamide primarily improves ventilatory control instability (expressed as loop gain), which is an important contributor to the pathophysiology of osa. few studies have assessed the efficacy of acetazolamide in patients with osa. since most of them had a small sample size and used different therapeutic dosages, clinical applications are currently limited. therefore, this study aims to compare the effect of two acetazolamide dosages on the severity and pathophysiology of osa.

in this double-blind, parallel-group, controlled trial, eligible patients will be randomized into one of the following treatment arms: (1) placebo, (2) 250 mg of acetazolamide, or (3) 500 mg of acetazolamide. after 4 weeks, treatment outcome will be assessed by in-laboratory polysomnography. additionally, arterial blood gas analysis and lung function tests will be performed before and during treatment.

Eligibility criteria:
inclusion criteria: * ahi between 15 and 65 events/hour * bmi \< 35 kg/m² exclusion criteria: * craniofacial anomalies * central sleep apnea (defined as central ahi \> 25% of total ahi) * contra-indications related to acetazolamide treatment * hypersensitivity to sulphonamides or acetazolamide * renal impairment, electrolyte imbalances, and/or adrenocortical insufficiency * clinically significant metabolic, hepatic, and/or hematological disease * chronic obstructive pulmonary disease * closed-angle glaucoma * conditions likely to affect osa physiology: neuromuscular disease or other major neurological disorders, heart failure, or any other unstable major medical condition. * intake of drugs that substantially stimulate or depress respiration, including benzodiazepines, opioids, theophylline, and pseudoephedrine * inadequately treated sleep disorders other than osa that would confound functional sleep assessment * inability of the patient to understand and/or comply to the study procedures * active psychiatric disease (psychotic illness, major depression, anxiety attacks, alcohol or drug abuse) * pregnancy

Keywords: carbonic anhydrase inhibitor treatment pharmacotherapy sleep apnea loop gain respiration ventilatory control instability acidosis
longitudinal mri examinations of patients with brain ischemia and blood brain barrier permeability

Conditions: Cerebral Stroke

Summary: the objective of this trial is to visualize blood brain barrier function and metabolic changes in the first days after ischemic stroke with new investigational mri sequences.

in this study the investigators will be examining acute ischemic stroke patients on the first and second day after symptom onset using repetitive mri examinations to visualize blood brain barrier function and metabolic changes of the brain in 5 sub-projects, each containing a specific mri protocol with one of the following new mri sequences: 1. t1-dynamics (measuring disruptions of the blood-brain barrier) 2. ph-imaging (measuring metabolic changes, acidosis) 3. resting-state mri (measuring changes in the cerebral perfusion) 4. quantitative mri-angiography (quantification of blood flow in single vessels) 5. diffusion tensor imaging (dti) for patients with anterior choroidal artery (acha)-infarcts (quantification of damage of white matter tracts) each sub-projects will be conducted in blocks of a specific time span. morphological outcome will be assessed at day 5-7. clinical outcome will be assessed at day 5-7 and day 90. the association of the new imaging parameter with the clinical and morphological outcome measures will be analysed. no specific intervention is assigned to the subjects by the investigators of the study.

Eligibility criteria:
inclusion criteria: * suspected stroke or transient ischemic attack (tia) within 24h from symptom onset exclusion criteria: * mri contraindication, age \< 18 years, intracranial hemorrhages

Keywords: acute ischemic stroke
left ventricular mass index predicts clinical outcomes in patients with obstructive hypertrophic cardiomyopathy undergoing septal myectomy

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Summary: in this study, we aimed to analyze the association between left ventricular mass index and clinical outcomes to provide the potential indicator for worse survival.

this retrospective study aimed to determine the prognostic value of left ventricular mass index in predicting clinical outcomes, including all-cause death, new-onset or recurrent atrial fibrillation, and a composite endpoint of all-cause death, heart failure,permanent pacemaker implantation, new-onset or recurrent atrial fibrillation, and stroke.

Eligibility criteria:
inclusion criteria:(1) difficulty in relieving symptoms with medication or recurrent syncope. (2) left ventricular outflow tract (lvot) pressure gradient ≥ 50 mmhg at rest or with provocation and the maximum thickness of the septum is ≧ 15 mm. exclusion criteria: * (1) combined right ventricular outflow tract obstruction requiring right ventricular outflow tract dissection. (2) combined mitral or aortic valve organic lesions requiring valve replacement surgery. (3) apical ventricular aneurysm formation requiring ventriculotomy. (4) previous septal reduction therapy, including alcohol ablation or septal myectomy. (5) patients did not undergo cardiac magnetic resonance examination.

Keywords: left ventricular mass index all-cause death survival obstructive hypertrophic cardiomyopathy septal myectomy
study of combination therapy with dimebon and donepezil (aricept) in patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to assess the safety and efficacy of dimebon in combination with donepezil (aricept) in the treatment of alzheimer's disease.


Eligibility criteria:
inclusion criteria: * alzheimer's disease * on donepezil (aricept) * caregiver who cares for the patient at least 5 days per week exclusion criteria: * unstable medical illnesses or significant hepatic or renal disease * other primary psychiatric or neurological disorders
evaluation of clinical success of restorations using different magnification aids

Conditions: Dental Caries

Summary: this study aimed to investigate the effect of using a loupe and dental operating microscope with different magnifications on the success of class ii direct composite restorations.

a total of 130 class ii, d2 deep caries teeth of 85 patients were randomly distributed to the naked eye, 3x magnification loupe, 5x magnification loupe, 8.5x magnification dental operating microscope (dom) groups, and direct composite restorations were made with these magnification aids. carried out. clearfil se bond 2 and clearfil majesty posterior composite were used in all restorations. the restorations were evaluated using fdi criteria at 1,6 and 12-month periods, and restorations were scored between 1 and 5 for all criteria.

Eligibility criteria:
inclusion criteria: * good oral and dental care of the patient, * the need for at least 1 class ii restoration at a depth of d2 in the posterior group teeth, * no crowding in the tooth to be restored, tooth contact and antagonist, * the relevant tooth is vital, * absence of pain on percussion and palpation of the tooth. * absence of any pathology in the periapical tissues in radiographic evaluation, * the patient was informed about the study and accepted the study, * having agreed to attend 1 month, 6 month and 12 month control sessions, * the patient has no systemic disease, exclusion criteria: * presence of severe periodontal disease, * teeth that cannot be insulated, malposed or overloaded or not loaded at all, * periodontal and endodontic removal of the relevant tooth is healthy, * the patient is undergoing orthodontic treatment, * recording of dry mouth is set, * severe bruxism habit, * smoking

Keywords: dental loupe restoration success fdi criteria
mindfulness to reduce post-cesarean pain and prevent postpartum depression

Conditions: Depression, Unipolar; Pain, Postoperative

Summary: this study will test the effect of a mobile mindfulness-based intervention on reducing post-cesarean delivery pain and preventing postpartum depression.

this clinical trial will test the effect of a mobile mindfulness-based intervention on reducing post-cesarean delivery pain and preventing postpartum depression.

Eligibility criteria:
inclusion criteria: * 18-45 years of age, have a singleton pregnancy, score less than 10 on the edinburgh postnatal depression scale (epds; (cox et al., 1987b), willing to participate in the eight-week intervention or be randomized to the taum condition, have no significant psychiatric disorders other than depression or anxiety (e.g., bipolar disorder, substance use disorder, etc.), have no chronic pain condition (e.g., fibromyalgia), and proficient in english or spanish exclusion criteria: * women who screen 10 or higher on the epds

Keywords: postpartum depression pain cesarean
short-and long-term effects of a home-based rehabilitation program in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: this study will investigate the short-and long-term effects of the home-based pulmonary rehabilitation on peripheral muscle strength, functional capacity and quality of life in patients with bronchiectasis. the participants will be randomized into two groups: control group (usual care and recommendations for practice exercise) and training group, that will perform aerobic (stepping training) and resistance training (lower and upper limbs) for eight weeks, three times a week. at baseline, immediately after finishing and after six months the patients will undergo assessments.

home-based pulmonary rehabilitation (hbpr) has been used in patients with chronic obstructive pulmonary disease, asthma and pulmonary fibrosis. results from hbpr have been similar to those observe in the outpatient pulmonary rehabilitation such improvement in exercise capacity, symptoms and quality of life. however, hbpr has not yet been investigated in patients with bronchiectasis, a progressive and debilitating disease with a high socioeconomic impact. objective: to investigate the short-and long-term effects of the home rehabilitation program in peripheral muscle strength, functional capacity and quality of life in patients with bronchiectasis. methods: patients diagnosed with bronchiectasis will be recruited from the obstructive diseases outpatient clinic of the hospital das clínicas - medicine school, university of são paulo. participants will be randomized into two groups: control group (usual care and recommendations for performing exercises and respiratory physiotherapy) and training group, that will perform aerobic (stepping training) and resistance training (lower and upper limbs) for eight weeks, three times a week. all patients will receive a phone call once a week and patients allocated to the training group, additionally, will get a home visit every 15 days. at baseline, immediately after finishing and after six months of the hbpr patients will undergo to assessments. expected results: hbpr will have positive effects on exercise tolerance and quality of life. also, this study will contribute to future guidelines on the recommendation of hbpr for patients with bronchiectasis.

Eligibility criteria:
inclusion criteria: clinical diagnosis and/or tomographic bronchiectasis clinically stable (no change in symptoms of dyspnea, in the amount and color of the secretion) have completed the outpatient pulmonary rehabilitation for more than a year not engaged in a regular physical activity. exclusion criteria: smokers with other lung related diseases (asthma, copd and cystic fibrosis) severe cardiovascular diseases musculoskeletal limitation unable to perform the tests and the training protocol due desaturation (pulse oxygen saturation ≤ 80%) over the recommended exercise intensity.

Keywords: bronchiectasis rehabilitation quality of life physiotherapy specialty
coronary drug project

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia

Summary: to determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

background: correlation of high levels of serum cholesterol with an increased incidence and prevalence of coronary heart disease (chd) was demonstrated--prior to the inception of the coronary drug project--repeatedly in prospective and cross-sectional epidemiological surveys (e.g., the tecumseh study, the framingham heart disease study). these findings led to the question of whether long-term lowering of serum lipids in individuals both with and without chd would have a beneficial effect on morbidity and mortality. the coronary drug project was designed to answer the question of secondary prevention. in 1961, dr. robert wilkins (boston university school of medicine) chaired an ad hoc committee which determined the desirability and feasibility of the conduct of this study. following national heart advisory council (nhac) support, a study policy board, steering committee, and coordinating center were established and a detailed protocol was written. in 1964, nhac approved the project and the nhi recommendation for implementation; the study was begun in 1965. supported by the grant mechanism, the trial involved 53 participating clinics, a coordinating center, central laboratory, ecg center, drug procurement and distribution center, and nhi medical liaison office, and a policy board, steering committee, and 12 other committees (e.g., a data and safety monitoring committee). the first patient was randomly allocated to treatment in march 1966 and the last in october 1969. each patient reported to the clinic every 4 months for a follow-up visit. design narrative: randomized, double-blind, fixed sample. a total of 8,341 patients were randomly assigned to six treatment groups consisting of 2.5 mg/day of conjugated estrogens, 5.0 mg/day of conjugated estrogens, 1.8 gm/day of clofibrate, 6.0 mg/day of dextrothyroxine sodium, 3.0 gm/day of niacin, or 3.8 gm/day of lactose placebo. the study completion date listed in this record was obtained from the query/view/report (qvr) system.

Eligibility criteria:
men, ages 30-64. three months beyond most recent myocardial infarction.
role of candidate proteins in capillary leakage during acute circulatory failure

Conditions: Cardiogenic Shock; Postresuscitation Disease; Septic Shock

Summary: * testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome. * describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans

circulatory shocks are responsible for one third of intensive care unit (icu) admissions (20,000 patients per year in france) and are associated with 40% mortality \[1,2\]. vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. during systemic inflammatory response syndrome (sirs), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure \[1,3\]. accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock \[4-7\] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure \[8-10\]. however, the determinants of vascular leakage remain poorly understood in humans. the purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.

Eligibility criteria:
inclusion criteria: 1. informed consent from patient or a legal representative/family member/close relative. the patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow. 2. affiliation to social security (ame excluded) 3. patient with one of the circulatory failures described below: * septic shock * cardiogenic shock * post-resuscitation syndrome * cardiogenic shock: * need for a catecholamine support to maintain mean arterial pressure\>65 mmhg, and * cardiac index \<2 l/min/m2 or left ventricular ejection fraction (lvef)\<35%, and * lactate \>2.0 mmol/l * post-resuscitation syndrome: * cardiac arrest (absence of spontaneous respiration, palpable heartbeat, and responsiveness to stimuli\> 1 min) with a compatible electrocardiogram (asystole/pulseless electrical activity/ventricular tachycardia), and * need for a catecholamine support to maintain mean arterial pressure\>65 mmhg, and * lactate \>2.0 mmol/l * septic shock: * suspected or proven bacterial infection * need for a vasopressor support to maintain mean arterial pressure\>65 mmhg * lactate \>2.0 mmol/l * cardiac index\>3l/min/m2 or lvef\>40% exclusion criteria: 1. onset of shock (catecholamine infusion) \>12 hours prior to inclusion 2. age \<18 year old 3. pregnancy
effects of natural sounds on attention restoration outdoors

Conditions: Cognitive Fatigue; Mental Fatigue; Behavioral Performance; Heart Rate Variability; Positive and Negative Affect; Inhibition, Psychological; Working Memory; Perceived Restoration

Summary: this study aims to examine whether listening to natural sounds in a noisy outdoor environment compared to no natural sounds influences behavioural, cognitive, affective, and physiological markers.

the investigators hypothesize that listening to natural sounds has restorative effects on attention by supporting greater use of involuntary attention. this generates the prediction that exposure to natural sounds in the context of a noisy outdoor environment will have greater restorative effects on attention (i.e., physiological, affective, cognitive, and behavioural) as compared to the control group (exposed to environmental noise only). individual differences (i.e., age, gender, caffeine and food intake, body mass index, skin temperature, noise sensitivity, sleep quality, baseline physiology and behavioural performance) will be examined and accounted for. environmental factors (i.e., outdoor humidity, temperature, and noise) will also be accounted for.

Eligibility criteria:
inclusion criteria: * singapore-based * non-clinical * 18-35years exclusion criteria: * individuals with hearing difficulties or failing to meet the minimal threshold for normal hearing * individuals with a history of ear, developmental, neurological, or psychiatric disorder